Repligen climbs as investors lean into 2026 growth guide and margin expansion plan
Repligen shares rose about 3% Tuesday as investors continued to digest the company’s upbeat Q4 2025 results and 2026 outlook released on February 24, 2026. Management guided 2026 revenue of $810 million to $840 million and projected about 150 basis points of adjusted operating margin expansion at the midpoint.
1. What’s moving the stock
Repligen (RGEN) traded higher Tuesday, extending a modest rebound that has followed its late-February earnings update. The company reported fourth-quarter 2025 revenue of $198 million (up 18% year over year) and said it saw continued momentum in orders during the quarter, which has supported a more constructive tone around near-term demand for its bioprocessing portfolio. (investors.repligen.com)
2. The latest fundamental catalyst investors are focusing on
The key reference point for investors remains Repligen’s 2026 framework issued February 24, 2026: revenue guidance of $810 million to $840 million (10% to 14% reported growth; 9% to 13% organic) and approximately 150 basis points of adjusted operating margin expansion at the midpoint. Management also flagged a two-point gene-therapy headwind embedded in the outlook, a detail that has been central to buy-side debate on how quickly growth normalizes. (investors.repligen.com)
3. Why it matters and what to watch next
With the stock reacting positively today, traders appear to be emphasizing the combination of growth and margin expansion rather than the gene-therapy drag. Next watch-items include updates on orders and end-market demand trends, plus any incremental commentary around the pace of recovery in filtration tied to gene therapy, which management has described as a meaningful but time-bound headwind to the 2026 growth rate. (investors.repligen.com)